FDA IND acceptance for ALA-101 enables phase 1 trials for CD19-positive cancers, supported by a strong leadership team and proprietary manufacturing. The pipeline expands into solid tumours with ALA-105 and IL-12-TM armouring, positioning for future growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.